A Phase 2 interventional study of LUM001 in Primary Sclerosing Cholangitis (PSC), sponsored by Mirum Pharmaceuticals, Inc.. Completed at 9 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-03-29.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Cholangitis, Sclerosing with a site in United States — 19 open to participants now, 22 under way, 2 of them phase 3. Cholangitis, Sclerosing · United States.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, this one is the 29th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2014, is one of 26 in phase 2, and was the 21st registered.
150 studies on the registry are indexed under Cholangitis, Sclerosing; 40 are open to participants now.
Browse Cholangitis, Sclerosing studies →19 of the 75 studies in Cholangitis, Sclerosing with a site in United States are open now. Recruiting first, the newest first:
Ipsen · Sites in United States, Argentina, Australia and 22 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–68 · Healthy volunteers
LISCure Biosciences · Sites in United States
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Elizabeth C. Verna · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 30 Cholangitis, Sclerosing studies recruiting now, 12 (40%) set no upper age limit and 13 (43%) stop at 75 or younger; 9 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 31 · Phase 3 6
First in 1997; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 33 across 95 interventional studies indexed under Cholangitis, Sclerosing.
Median enrollment 27 across the 57 interventional studies, 129 across the 18 observational. Of the 48 that completed or were terminated, 25 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 75 have an industry lead sponsor. The 10 most frequent:
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
Mirum Pharmaceuticals, Inc. has 3 studies filed under Cholangitis, Sclerosing — fewer than ten, so there is no comparison to draw.
4 of the studies in Cholangitis, Sclerosing with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06197308University of MinnesotaEvaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | 2027-03-31 |
| NCT05295680Aparna GoelOral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | 2027-05 |
| NCT05835505Brigham and Women's HospitalDetoxification of the Liver In PSC (Dolphin) | 2027-05-01 |
| NCT05912387Stanford UniversityStatin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | 2027-05-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Cholangitis, Sclerosing with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study is an open-label study in adults with primary sclerosing cholangitis to evaluate the safety, tolerability, and effect of 14-weeks of daily dosing of LUM001.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LUM001 administered orally once each day
Drug: LUM001
LUM001 oral dose
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An Adverse Event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. TEAEs were AEs with a start date on or after the first dose of investigational product and started prior to the last dose of investigational product plus 14 days.
Time frame: From start of study drug administration until Week 18
Change From Baseline in Fasting Serum Bile Acid Level at Week 14
Serum bile acid levels were evaluated using blood samples collected.
Time frame: Baseline, Week 14
Change From Baseline in Liver Enzyme Levels in Serum
Levels of liver enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) in serum were evaluated.
Time frame: Baseline, Week 14
Change From Baseline in Bilirubin Levels at Week 14
Total Bilirubin and Direct (Conjugated) Bilirubin levels were evaluated.
Time frame: Baseline, Week 14
Change From Baseline in Pruritus as Measured by Adult Itch Reported Outcome (ItchRO) Weekly Sum Score
The Adult ItchRO instrument was completed twice daily using an electronic diary (eDiary). Each morning and evening score had a range from 0-10, with the higher score indicating increasing itch severity. The following was used for assessing the Adult ItchRO daily score: The score which represented the most severe itching for the day (morning or evening) was taken for each day as the daily score (maximum daily score of 10); If only 1 of the 2 scores was available for the day, the score that was available was used as the daily score; If both the morning and the evening scores were missing, the score was considered missing for the day.
Time frame: Baseline, Week 14
Change From Baseline for Other Biochemical Markers of Cholestasis: Total Cholesterol, Low Density Lipoprotein Cholesterol
Total cholesterol (TC) level and low density lipoprotein cholesterol (LDLC) level were considered as biochemical markers of cholestasis.
Time frame: Baseline, Week 14
The study was conducted in 8 centers in Great Britain, Canada, and the United States between 22 April 2014 and 12 February 2016.
| Milestone | Maralixibat (LUM001) |
|---|---|
| Started | 27 |
| Down-titrated on lum001 during the study | 5 |
| Completed | 23 |
| Not completed | 4 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 2 |
An Adverse Event (AE) was defined as any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered to be related to the investigational drug product. TEAEs were AEs with a start date on or after the first dose of investigational product and started prior to the last dose of investigational product plus 14 days.
| participant | Maralixibat (LUM001) 1 mg | Maralixibat (LUM001) 2.5 mg | Maralixibat (LUM001) 5 mg | Maralixibat (LUM001) 7.5 mg | Maralixibat (LUM001) 10 mg |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 1 | 2 | 2 | 1 | 19 |
Serum bile acid levels were evaluated using blood samples collected.
| micromoles per liter | Maralixibat (LUM001) |
|---|---|
| Baseline | 38.941 ± 38.6614 |
| Change From Baseline | -14.841 ± 31.3709 |
Levels of liver enzymes such as Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) in serum were evaluated.
| units per liter (U/L) | Maralixibat (LUM001) |
|---|---|
| ALT: Baseline | 108.5 ± 78.95 |
| ALT: Change From Baseline | 10.5 ± 63.07 |
| AST: Baseline | 88.3 ± 43.70 |
| AST: Change From Baseline | 11.7 ± 34.14 |
| ALP: Baseline | 471.6 ± 316.93 |
| ALP: Change From Baseline | 36.7 ± 170.87 |
Total Bilirubin and Direct (Conjugated) Bilirubin levels were evaluated.
| milligram per deciliter (mg/dL) | Maralixibat (LUM001) |
|---|---|
| Total Bilirubin Level: Baseline | 1.22 ± 0.775 |
| Total Bilirubin Level: Change From Baseline | 0.24 ± 0.666 |
| Conjugated Bilirubin Level: Baseline | 0.60 ± 0.510 |
| Conjugated Bilirubin Level: Change From Baseline | 0.19 ± 0.450 |
The Adult ItchRO instrument was completed twice daily using an electronic diary (eDiary). Each morning and evening score had a range from 0-10, with the higher score indicating increasing itch severity. The following was used for assessing the Adult ItchRO daily score: The score which represented the most severe itching for the day (morning or evening) was taken for each day as the daily score (maximum daily score of 10); If only 1 of the 2 scores was available for the day, the score that was available was used as the daily score; If both the morning and the evening scores were missing, the score was considered missing for the day.
| units on scale | Maralixibat (LUM001) |
|---|---|
| Baseline | 15.00 ± 18.735 |
| Change From Baseline | -7.67 ± 16.326 |
Total cholesterol (TC) level and low density lipoprotein cholesterol (LDLC) level were considered as biochemical markers of cholestasis.
| mg/dL | Maralixibat (LUM001) |
|---|---|
| TC Level: Baseline | 213.0 ± 50.62 |
| TC Level: Change From Baseline | -21.2 ± 25.46 |
| LDLC Level: Baseline | 121.4 ± 40.52 |
| LDLC Level: Change From Baseline | -16.3 ± 17.64 |
Collected over From start of study drug administration up to follow up (Week 18). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Maralixibat (LUM001) | — | 4/27 (14.8%) | 25/27 (92.6%) |
| Event | Maralixibat (LUM001) |
|---|---|
| MelaenaGastrointestinal disorders | 1/27 |
| Upper gastrointestinal haemorrhageGastrointestinal disorders | 1/27 |
| AppendicitisInfections and infestations | 1/27 |
| Joint dislocationInjury, poisoning and procedural complications | 1/27 |
| CholangitisHepatobiliary disorders | 1/27 |
| Event | Maralixibat (LUM001) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 14/27 |
| NauseaGastrointestinal disorders | 9/27 |
| Abdominal painGastrointestinal disorders | 8/27 |
| HeadacheNervous system disorders | 6/27 |
| Abdominal distensionGastrointestinal disorders | 4/27 |
| FatigueGeneral disorders | 4/27 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/27 |
| Abdominal discomfortGastrointestinal disorders | 3/27 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 2/27 |
| Neck painMusculoskeletal and connective tissue disorders | 2/27 |
Safety population included all participants who received at least 1 dose of the investigational product.
| Age, Continuous(Years) | Maralixibat (LUM001) |
|---|---|
| Mean | 43.7 ± 11.35 |
| Sex: Female, Male(Participants) | Maralixibat (LUM001) |
|---|---|
| Female | 9 |
| Male | 18 |
The record gives a start of Mar 2014, a primary completion of Feb 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat